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Background
Infliximab has been shown to be beneficial in treating
pediatric uveitis. No data exist on optimal dosing and
true efficacy of higher dosing.
Objectives
To compare the efficacy of low dose (LD) infliximab
(<10mg/kg), moderate dose (MD) infliximab (≥10-15mg/
kg) and high dose (HD) (≥15-20mg/kg) in the treatment
of various forms of uveitis.
Methods
We conducted a retrospective study at Children’s Hospi-
tal Los Angeles and Miller Children’s Hospital, Los
Angeles. We performed comprehensive medical record
review to identify demographic information and clinical
data. Ocular outcome was assessed by anterior chamber
cell density, flare, visual acuity, intra ocular pressure and
ability to reduce or stop concomitant topical or systemic
steroids.
Results
The mean age of patients was 11.2 years and mean
duration of uveitis was 33 months. All patients had
bilateral eye disease. 71% of children had preexisting
complications including glaucoma and cataracts. Of the
34 patients, there were 6 (18%), 19 (56%) and 9 (26%)
patients in LD, MD and HD group respectively.
Characteristics, duration of uveitis and response to
therapy are described (Table 1).




Anatomic classification of Uveitis among cohort (%)
Anterior Uveitis 100 31 33
Intermediate Uveitis 0 <1 1
Posterior Uveitis 0 26 33
Panuveitis 0 42 44
Mean age at diagnosis of uveitis (yrs) 8.9 8.4 8.5
Mean age of onset of treatment (yrs) 10.8 10.9 12.1
Mean duration of other medication regimens prior to infliximab (yrs) 2.0 2.6 3.5
Duration of treatment with topical steroids prior to infliximab (mo) 10.6 12.3 15.4
Time to discontinuation of steroids after infliximab (mo) 3.1 9.5 10.2
Patients requiring dose escalation (%) 67 35 55
Average time to dose escalation (mo) 5.1 7.5 14
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Conclusion
We found that treatment with infliximab is beneficial
and that dose escalation up to 4 times above the
approved dose is often necessary to achieve disease con-
trol. LD infliximab was found not to be sufficient in dis-
ease control. Although we found MD to be effective,
one third of patients in this group required escalation
for better disease control. Despite escalated doses, treat-
ment appeared safe in the short term and no adverse
events were observed.
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